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Background: The roles of circulating endothelial progenitor cell (EPC) and mononuclear cell apoptosis (MCA)
in liver cirrhosis (LC) patients are unknown. Moreover, vascular endothelial growth factor (VEGF) and stromal
cell-derived factor (SDF)-1α are powerful endogenous substances enhancing EPC migration into circulation.
We assessed the level and function of EPCs [CD31/CD34 (E1), KDR/CD34 (E2), CXCR4/CD34 (E3)], levels of MCA,
VEGF and SDF-1α in circulation of LC patients.
Methods: Blood sample was prospectively collected once for assessing EPC level and function, MCA, and plasma
levels of VEGF and SDF-1α using flow cytometry and enzyme-linked immunosorbent assay (ELISA), respectively,
in 78 LC patients and 25 age- and gender-matched healthy controls.
Results: Number of EPCs (E1, E2, E3) was lower (all p< 0.0001), whereas SDF-1α level and MCA were higher
(p< 0.001) in study patients compared with healthy controls. Number of EPCs (E2, E3) was higher but MCA was
lower (all p< 0.05) in Child's class A compared with Child's class B and C patients, although no difference in VEGF
and SDF-1α levels were noted among these patients. Chronic hepatitis B and esophageal varices bleeding were
independently, whereas chronic hepatitis C, elevated aspartate aminotransferase (AST), and decompensated LC
were inversely and independently correlated with circulating EPC level (all p< 0.03). Additionally, angiogenesis and
transwell migratory ability of EPCs were reduced in LC patients than in controls (all p< 0.001).
Conclusion: The results of this study demonstrated that level, angiogenic capacity, and function of circulating EPCs
were significantly reduced, whereas plasma levels of SDF-1α and circulating MCA were substantially enhanced in
cirrhotic patients.
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Since multitudinous studies have shown that circulating
endothelial progenitor cells (EPCs) are essential for
neoangiogenesis and the endothelial repair process, they* Correspondence: han.gung@msa.hinet.net
4Division of Cardiology, Department of Internal Medicine, Kaohsiung Chang
Gung Memorial Hospital and Chang Gung University College of Medicine,
123, Ta Pei Road, Niao Sung Hsiang, Kaohsiung Hsien 83301, Taiwan
6Center for Translational Research in Biomedical Sciences, Kaohsiung Chang
Gung Memorial Hospital and Chang Gung University College of Medicine,
Kaohsiung, Taiwan
Full list of author information is available at the end of the article
© 2012 Chen et al.; licensee BioMed Central L
Commons Attribution License (http://creativec
reproduction in any medium, provided the orhave been employed for the treatment of both experi-
mental and clinical organ ischemia in various settings
over the past few years [1-6]. Growing data have demon-
strated that EPC migration into circulation and homing
to ischemic tissues/organs are strongly associated with
an increase in circulating levels of chemokines [7], cyto-
kines [8], recombinant human erythropoietin (EPO) [9],
and some specific medications such as statins [10] or
angiotensin converting enzyme inhibitors (ACEIs) [11],
as well as extracorporeal shock wave therapy [12].
Additionally, angiogenesis in malignant tumors andtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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an increased number of circulating EPCs [13,14]. Be-
sides, vascular endothelial growth factor (VEGF) and
stromal cell-derived factor-1 alpha (SDF-1α), two power-
ful soluble angiogenesis factors, have been shown to play
a crucial role in enhancing EPC migration from bone
marrow into circulation [15]. Conversely, decreased cir-
culating number of EPCs has been found to correlate to
the prevalence of risk factors for coronary artery disease
[16,17], recurrent ischemic stroke [18], and advanced
heart failure [19].
Liver cirrhosis (LC) of divergent etiologies is at high
risk of developing into hepatocellular carcinoma (HCC)
[20,21]. Moreover, abundant studies have shown that not
only serum levels of soluble angiogenic factors are not-
ably increased in patients with LC and those with HCC,
but they are also useful biomarkers for predicting the
prognostic outcome in these patient populations [22-24].
Surprisingly, the role of circulating EPCs in the clinical
setting of LC has seldom been investigated [25]. Besides,
the link between circulating number of EPC and plasma
level of VEGF and SDF-1α is currently unclear in LC
patients. Furthermore, although progression of chronic
liver disease to LC is known to involve distinctive
apoptosis and death of hepatocytes, there is a lack of
in-depth scrutiny regarding the role of circulating
mononuclear cell apoptosis (MCA) in modulating the
severity of chronic liver disease. Of particular import-
ance is that the function of EPC in LC patients has not
been reported. In this study, the above issues were
addressed by applying flow cytometric and ELISA ana-
lysis to determine the number and function of EPCs, the
distinctive role of circulating MCA, and the relationship
between EPC biomarkers and plasma levels of VEGF
and SDF-1α in LC patients.
Methods
Patient enrollment and blood sampling
The estimated sample size of 86 patients was based on
the effective size with an α value of 0.05, a power of
80 %, a 0.7 % difference in circulating level of EPCs be-
tween study patients and healthy control subjects, and
standard deviations of 0.7 % in normal control subjects
and 1.0 % in study patients. A 12.0 % rate of protocol
violations was assumed. The calculation of sample size
for specific objective was based on our recent report
[18]. The expected 0.7 % was based on our previous
study of EPC surface marker of CD31/CD34 on 138
patients [18].
To circumvent other potential influences on measure-
ment of circulating level of EPCs, patients with one or
more of the followings were excluded: recent surgery or
trauma during the preceding 2 months, malignancy, his-
tory of febrile disorders, acute or chronic inflammatorydisease other than LC during the study period, history of
autoimmune diseases with or without immunosuppressive
therapy, and prior myocardial infarction with an onset
of< 3 months.
Between September 2009 and December 2010, 88
patients who presented to the Department of Gastro-
enterology at Kaohsiung Chang Memorial Hospital with
the diagnosis of LC were recruited. Patients were en-
rolled either from out patient department (n = 7, all of
them were Child’s class A patients) (followed-up for LC)
or during hospitalization (n = 71) for severe jaundice, as-
cites with hypoalbuminemia for plasma transfusion,
acute aspartate aminotransferase (AST) and alanine ami-
notransferase (ALT) elevation, anti-hepatitis B (enteca-
vir) treatment, anti-hepatitis C (interferon) treatment,
esophageal varices ligation or esophageal varices bleed-
ing (n = 10). After excluding 10 patients due to infection
or refusing to participate in the study, blood sampling
was performed in totally 78 consecutive patients. All
blood sampling was collected prior to blood transfusion.
Twenty-five age- and gender-matched healthy controls
were also studied. Informed consent was obtained from
all study subjects. The study protocol was approved by
the Institutional Review Committee on Human Research
at Kaohsiung Chang Gang Memorial Hospital.
Subgroup analysis of the patients
According to the degree of decompensation in liver
function, the study patients were categorized into Child's
class A, B, and C to investigate whether the circulating
levels of EPCs, MCA, and plasma levels of SDF-1α and
VEGF were different among these patients.
Ultrasonographic examination and definitions
Ultrasonographic scans were performed by experienced
hepatologists at our institute using an ultrasound system
with a 3.5 MHz convex probe (SSA-340, SSA-370,
Aplioxu-700 Toshiba, Tokyo, Japan; SSD 2000, Aloka,
Tokyo, Japan; HDI 5000, ATL Ultrasound, Bothell, USA;
Preirus Hi-vision Hitachi, Tokyo, Japan).
Chronic hepatitis C was defined as detectable serum
antibody to hepatitis C virus (anti-HCV), and chronic
hepatitis B was defined as detectable serum hepatitis B
viral surface antigen (HBsAg). The definitions and diag-
noses of HCC, LC, and the degree of decompensation
were based on previous reports [26-30].
Blood sampling and assessment of circulating EPC level
by flow cytometry
Blood samples were obtained once in ward or in the out-
patient department for the study group and also once
for the healthy control subjects. Twenty milliliters of
blood was drawn from the antecubital vein (10 mL for
EPC analysis and another 10 mL for MCA assessment).
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density-gradient centrifugation of Ficoll 400 (Ficoll-Pla-
queTM plus, Amersham Biosciences, Sweden) as previ-
ously described [31]. The isolated MNCs were washed
twice with phosphate buffer solution (PBS) and centri-
fuged before incubation with 1 mL blocking buffer
(BSA) for 30 minutes at 4 0 C. Cell viability of> 95.0 %
was noted in each group.
It has been reported that EPCs are characterized by
surface expression of CD34, CD31, CXCR4 and kinase
insert domain-conjugating receptor (KDR) antigens
[9,12,18,19,31,32]. In this study, EPCs were defined as
cells with co-expression of CD34, endothelial cell (EC)
lineage-markers [KDR, vascular endothelial (VE)-cad-
herin, CD31, and CXCR4 according to previous reports
[9,12,18,19,31,32] and our recent study [18].
EPCs in peripheral blood were identified by flow cyto-
metry using the technique of double staining as depicted
in our recent report [18]. To determine the EPC surface
markers of CD31/CD34 (E1), KDR/CD34 (E2) and
CXCR4/CD34 (E3), MNCs (4 x 10
5) were incubated for
30 minutes at 4 0 C in a dark room with monoclonal
antibodies against KDR (Sigma), fluorescein isothiocyan-
ate (FITC)-conjugated CD34, phycoerythrin (PE)-conju-
gated CD31, and CXCR4 (Becton Dickinson). Control
ligand (IgG-PE conjugate) was used to detect possible
nonspecific association and define a threshold for glyco-
protein binding. For analysis of KDR, MNCs were further
incubated with goat anti-mouse antibody conjugated
with PE. After staining, the MNCs were fixed in 1 % par-
aformaldehyde. Quantitative two-color flow cytometric
analysis was performed using a fluorescence-activated
cell sorter (FACSCaliburTM system; Beckman). Each ana-
lysis included 30,000 cells (i.e., mononuclear cells) per
sample. The assays for EPCs (E1-3) in each sample were
performed in duplicate and the mean levels were
reported. The results were expressed as percentage (%) of
total mononuclear cells per sample.
Intra-assay variability based on repeated measurement
of the same blood sample was low with a mean coeffi-
cient of variance of 4.6 % in LC patients and 4.1 % in
healthy control subjects.
Mononuclear cell culture, differentiation of endothelial
cell phenotype, angiogenesis, and measurement of total
tubular length
To evaluate the degree of angiogenesis, another 10 mL
of blood was drawn randomly from 6 LC patients (2 in
Child’s Class A, B and C, respectively) and 6 normal
subjects with age match, respectively. The protocol and
procedure of cell culture and the determination of
angiogenesis were based on our recent report [33].
Briefly, the MNCs were isolated by density-gradient cen-
trifugation of Ficoll 400, followed by cultivation indifferential endothelial cell culture medium (endothelial
cell basal medium-2, Cambrex) with 10 % fetal bovine
serum (FBS), 50 U/mL penicillin, 50 μg/mL strepto-
mycin and 2 mmol/L L-glutamine (Invitrogen) with
VEGF and basic fibroblast growth factor (10 ng/ml) pla-
ted on gelatin-coated tissue culture flasks and incubated
at 37 0C with 5 % CO2 for 21 days. Culture medium was
changed every 48 hours. By day 21, cells with spindle-
shaped and cobblestone-like phenotype typical of endo-
thelial cells were found attached on the plate.
The cells with endothelial cell phenotype were then
plated in 96-well plates at 1.0 × 104 cells/well in 150 μL
serum-free M199 culture medium mixed with 50 μL
cold Matrigel (Chemicon international) for 24 hours
using passage 2 EPCs incubated at 37 °C in 5 % CO2.
Three random microscopic images (200 x) were taken
from each well for counting cluster, tube, and network
formations with the mean values obtained. Both cumula-
tive and mean tube lengths were calculated by Image-
Pro Plus software (Media Cybernetics).
Transwell migratory assay
To investigate the transwell migratory ability of EPCs
(n = 6 in each experiment), transwell membranes (5 μm;
Costar, Germany) were coated on both sides with fibro-
nectin (2.5 μg/mL; Roche, Mannheim, Germany) over-
night at 4 °C. The experimental protocol was also based
on that of our recent report [32]. EPCs (1 x 105 cells/
well) were resuspended in M199 medium (Gibco, Carls-
bad, CA, USA) containing 0.5 FBS (Gibco, Carlsbad,
CA, USA) and incubated in the upper chamber at 37 °C
in 5 % CO2 and allowed to migrate for 18 hours toward
the lower chamber which was filled with M199 contain-
ing 20 % FBS. Cells remaining on the upper surface of
the transwell membranes were mechanically removed
and cells that had migrated to the lower surface were
fixed with 4 % formaldehyde. For cell quantification, nu-
clei of the migrated cells were stained with DAPI. Cells
migrating into the lower chamber were counted in 5
random microscopic fields using a fluorescence micro-
scope (Olympus, Tokyo, Japan) with the software Image-
Pro Plus (Media Cybernetics, Bethesda, MD, USA).
Determination of annexin V level by flow cytometry
Flow cytometric analysis using double staining of
annexin V and propidium iodide (PI) is a simple and
popular method for the identification of apoptotic cells
[i.e. early phase (annexin V+/PI-) and late phase
(annexin V+/PI+) of apoptosis].
Ten milliliters of peripheral blood MNCs were isolated
by density gradient centrifugation of Ficoll 400 (Ficoll-
PlaqueTM plus, Amersham Biosciences, Sweden). Cell
viability of> 95.0 % was noted in each group. The proto-
col and procedure were based on our recent report [33].
Chen et al. Journal of Biomedical Science 2012, 19:66 Page 4 of 11
http://www.jbiomedsci.com/content/19/1/66The annexin V kit (Pharmingen, Becton Dickinson,
San José, CA, USA) was used for apoptosis analysis
according to the manufacturer’s instructions. The super-
natant was decanted and the pellet was resuspended in
200 μL of 1x annexin V binding buffer. Cells were incu-
bated with 2 μL of annexin V-FITC and 5 μL of propi-
dium iodide (PI) for 15 minutes at room temperature in
the dark. Finally, 500 μL of 1x annexin V Binding Buffer
was added, followed by immediate flow cytometric ana-
lysis. Identical to the analysis of EPCs, each analysis
included 30,000 cells (i.e., mononuclear cells) per sam-
ple. The assays for MCA in each sample were performed
in duplicate and the mean levels were reported. The
results were expressed as percentage (%) of total mono-
nuclear cells per sample.
Intra-assay variability based on repeated measure-
ments of the same blood sample was low with a mean
coefficient of variance less than 4.2 % in both study
patients and normal subjects.
Measurement of plasma levels of VEGF and SDF-1α using
ELISA
Plasma concentrations of VEGF and SDF-1α were
assessed using VEGF and SDF-1α antibody ELISA kit
(R&D), respectively according to the manufacturer's
protocol.
Statistical analysis
Data were expressed as means ± SD. Continuous data
between two groups were analyzed using Wilcoxon rank
sum test, and categorical data were analyzed by chi-
square or Fischer exact test. For determining statistical
significance among the three groups, continuous data
were analyzed using Kruskal-Wallis test, followed by
Wilcoxon rank sum test with Bonferroni’s correction.
Statistical analysis was performed using SAS statistical
software for Windows version 8.2 (SAS institute, Cary,
NC). A p value of< 0.05 was considered statistically
significant.
Results
Table 1 shows the baseline characteristics and laboratory
findings of study patients and healthy control subjects.
The age, gender, white blood cell (WBC) count, and serum
creatinine level did not differ between the two groups.
However, the circulating level of EPCs [CD31/CD34(E1),
KDR/CD34(E2), CXCR4/CD34(E3)], hemoglobin level,
platelet count, and serum albumin concentration were re-
markably lower in study patients than those in control
subjects. By contrast, the serum levels of AST, ALT, and
plasma level of SDF-1α were substantially increased in
study patients compared with those in control subjects,
whereas plasma VEGF level was similar between the two
groups. Additionally, flow cytometry revealed a notableenhancement of early and late MCA in LC patients than
in healthy control subjects in the present study (Table 1).
The incidences of male gender, diabetes mellitus,
hypertension, and current smoking did not differ
among Child's class A, B and C patients (Table 2). The
incidences of chronic hepatitis B, chronic hepatitis C,
history of esophageal varices (EV) bleeding, ascites on
sonographic examination, and portal venous hyperten-
sion were similar among the three groups of patients.
However, patients in the Child's class C were younger
than the other two groups. Additionally, the incidences
of decompensated LC and portal venous hypertension
were remarkably higher in patients in Child's class C
than those in Child's class A and B, and notably higher
in patients in Child's class B than those in Child's class
A. Furthermore, the incidences of current smoking and
splenomegaly were significantly higher in Child's class B
and C patients than those in Child's class A, but they
showed no difference between those in Child's class B
and C.
Flow cytometric analysis (Table 3) demonstrated that
the circulating number of E2 and E3 was significantly
increased in Child's class A patients than those in Child's
class B and C, but the number of E1, E2 and E3 did not
differ between those in Child's class B and C.
To elucidate the impact of decompensation of liver
function on MCA in circulation, flow cytometric analysis
using the technique of double staining for annexin V
and PI was performed for each patient. The results
showed that early MCA was similar among the three
groups of the patients, whereas late MCA was substan-
tially lower in those in Child's class A than those in
Child's class B and C. No significant difference, however,
was noted between patients in Child's class B and C.
Laboratory findings demonstrated no significant differ-
ences in hemoglobin, WBC count, platelet count, serum
levels of creatinine, AST, ALT, and α-fetoprotein among
the three groups of patients. On the other hand, pro-
thrombin time and serum level of total bilirubin were
significantly lower in Child's class A than in Child's class
B and C patients. These two parameters, however, did
not differ between Childs' class B and C patients. Para-
doxically, serum albumin level was notably lower in
Child's class A than in Child's class B and C patients.
The plasma level of SDF-1α was similar among the
three groups of patients. In addition, although no sig-
nificant difference in plasma level of VEGF was noted
between Child's class B and C patients, it was signifi-
cantly lower in Child's class A than in Child's class B
and C patients.
To compare the number of circulating EPCs and
plasma levels of VEGF and SDF-1α among LC patients
with (n = 66) or without HCC (n =12) and the healthy
control (n = 25) subjects, subgroup analysis was
Table 1 The baseline Characteristics of Study Patients and Normal Controls
Variables Study patients (n = 78) Normal control (n = 25) p value*
Age (yrs) 54.8 ± 13.7 54.1 ± 10.5 0.927
Male gender 71.8 % (56) 68.0 % (17) 0.716
EPC surface markers†
CD31/CD34 (%){ 1.01 ± 0.57 1.37 ± 0.49 0.005
KDR/CD34 (%){ 1.08 ± 0.63 1.37 ± 0.65 0.035
CXCR4/CD34 (%){ 1.13 ± 0.66 1.54 ± 0.64 0.001
WBC count (x 103/dl) 8.5 ± 11.9 6.0 ± 1.5 0.575
Hemoglobin (g/dl) 10.9 ± 2.4 14.9 ± 1.3 <0.0001
Platelet count (x 104/dl) 10.8 ± 6.3 22.4 ± 5.5 <0.0001
Creatinine (mg/dl) 1.00 ± 0.60 0.91 ± 0.20 0.806
Albumin (g/dl) 3.0 ± 0.6 4.5 ± 0.3 <0.0001
AST (U/L) 97.8 ± 107.1 24.6 ± 6.4 <0.0001
ALT (U/L) 68.1 ± 123.0 29.3 ± 17.4 0.005
VEGF (pg/ml) 55.4 ± 58.0 49.9 ± 27.8 0.286
SDF-1α (pg/ml) 2256.3 ± 705.8 1502.4 ± 370.7 <0.0001
Early apoptosis (%) 18.01 ± 11.66 6.16 ± 2.83 <0.0001
Late apoptosis (%) 3.28 ± 3.86 1.19 ± 0.99 0.0008
Data expressed as mean ± SD or % (No).
ALT = alanine aminotransferase; AST = aspartate aminotransferase; EPC= endothelial progenitor cell; SDF = stromal cell-derived factor; VEGF = vascular endothelial
cell growth factor; WBC =white blood cell.
* by Wilcoxon rank sum test.
† indicates EPC surface markers with double stains.
{ The expected 0.7 % was based on our previous study [18] on EPC surface markers (CD31/CD34). The expected difference (i.e., 0.7 %) has not been reached for
CD31/CD34 (or KDR/CD34, CXCR4/CD34) in Table 1.
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did not differ among LC patients and healthy controls.
Additionally, the numbers of circulating E1 were similar
between LC patients with or without HCC. Furthermore,Table 2 Clinical Characteristics and Abdominal Ultrasonograp
Variables Child’s class A (n= 9) Chi
Age (yrs) 59.9 ± 11.3 a 59.6
Male gender 55.6 % (5) 65.%
Diabetes mellitus 33.3 % (3) 46.2
Hypertension 22.2 % (2) 11.5
Current smoking 11.1 % (1)a 73.1
Chronic hepatitis B 55.6 % (5) 38.5
Chronic hepatitis C 11.1 % (1) 30.8
Previous EV bleeding 22.2 % (2) 30.8
Hepatocellular carcinoma 0 % (0) 23.1
Liver cirrhosis 100.0 % (9) 100
Ascitis 22.2 % (2) 50.0
Decompensated liver cirrhosis 11.1 % (1)a 38.5
Splenomegaly 22.2 % (2)a 76.9
Portal vein hypertension 11.1 % (1)a 30.8
Data expressed as mean ± SD or % (No).
EV, esophageal varices.
*Continuous data were analyzed using Kruskal-Wallis test; categorical data were ana
indicate significant difference (at 0.05 level) (by Wilcoxon rank sum test with Bonferthe number of circulating E1 did not differ between LC
with HCC and healthy controls, but it was significantly
lower in LC patients without HCC than in healthy con-
trols. Moreover, the circulating number of E3 did nothic Findings of 78 Study Patients
ld’s class B (n= 26) Child’s class C (n = 43) p value*
± 14.4 a 50.8 ± 12.7 b 0.030
(17) 79.1 % (34) 0.234
% (12) 20.9 % (9) 0.089
% (3) 2.3 % (1) 0.0503
% (19)b 48.8 % (21)b 0.006
% (10) 27.9 % (12) 0.251
% (8) 10 (23.3 %) 0.513
% (8) 46.5 % (20) 0.295
% (6) 14.0 % (6) 0.286
.0 % (26) 100.0 % (43) 1.000
% (13) 58.1 % (25) 0.136
% (10)b 67.4 % (29)c 0.002
% (20)b 67.4 % (29)b 0.015
% (8)b 53.5 % (23)c 0.028
lyzed using Chi-square or Fisher’s exact test appropriately. Letters (a, b, C)
roni’s correction).
Table 3 Flow Cytometric Analysis and Laboratory Findings of 78 Study Patients
Variables Child’s class A (n = 9) Child’s class B (n = 26) Child’s class C (n =43) p value*
EPC surface makers (double stains)
CD31/CD34 (%) 1.23 ± 0.44 0.90 ± 0.52 1.03 ± 0.61 0.279
KDR/CD34 (%) 1.60 ± 0.51a 0.97 ± 0.63b 1.03 ± 0.61b 0.013
CXCR4/CD34 (%) 1.49 ± 0.56a 1.20 ± 0.63b 1.00 ± 0.61b 0.043
Early apoptosis (%) 13.5 ± 8.9 16.8 ± 10.8 19.7 ± 12.5 0.281
Late apoptosis (%) 1.66 ± 1.62a 3.12 ± 4.50b 3.67 ± 3.7b 0.046
Hemoglobin (g/dl) 12.2 ± 2.2 10.1 ± 2.5 11.1 ± 2.2 0.110
WBC count (x 103/dl) 5.0 ± 2.1 8.7 ± 12.5 8.8 ± 12.3 0.700
Platelet count (x 104/dl) 13.6 ± 11.9 11.0 ± 5.5 10.3 ± 5.7 0.930
Creatinine (mg/dl) 0.84 ± 0.23 0.93 ± 0.34 1.08 ± 0.74 0.805
Albumin (g/dl) 2.54 ± 0.33a 2.89 ± 0.54b 2.87 ± 0.58b 0.005
AST (U/L) 50.0 ± 23.6 114.0 ± 152.1 98.0 ± 80.4 0.097
ALT (U/ml) 45.0 ± 32.5 83.6 ± 195.2 63.5 ± 67.7 0.361
Prothrombin time (sec) 11.0 ± 0.7a 13.6 ± 3.9b 13.2 ± 2.2b 0.006
α-fetoprotein (ng/ml) 8.3 ± 3.2 75.8 ± 223.5 1187.5 ± 6495.3 0.430
Total bilirubin (mg/dl) 0.8 ± 0.2a 3.4 ± 3.2b 4.8 ± 6.4b 0.0002
VEGF (pg/ml) 25.0 ± 11.4a 54.1 ± 22.4b 62.6 ± 59.8b 0.039
SDF-1α (pg/ml) 2030.1 ± 446.4 2246.1 ± 808.0 2309.8 ± 687.6 0.350
Data expressed as mean ± SD or % (No).
ALT =Alanine aminotransferase; AST = aspartate aminotransferase; SDF = stromal cell-derived factor; VEGF = vascular endothelial cell growth factor; WBC =white
blood cell.
* Continuous data were analyzed using Kruskal-Wallis test. Letters (a, b) indicate significant difference (at 0.05 level) (by Wilcoxon rank sum test with Bonferroni’s
correction).
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trol subjects. Interestingly, this biomarker (E3) in LC
patients without HCC was not only notably lower than
in healthy subjects but it was also significantly lower
than in LC patients with HCC (Figure 1A). The plasma
level of VEGF showed no difference either between LC
patients with and without HCC, or between LC patients
without HCC and healthy subjects. This biomarker,
however, was notably elevated in patients with HCC
compared with that in healthy subjects (Figure 1B). Add-
itionally, the plasma level SDF-1α did not differ between
LC patients with or without HCC, or between LC
patients without HCC and healthy subjects, but it
showed significantly higher in LC patients with HCC
than in healthy subjects (Figure 1C). These findings
imply that LC patients with HCC might have higher
ability than those with LC alone to secrete SDF-1α and
VEGF that, in turn, enhanced the mobilization of EPCs
from bone marrow to circulation.
To identify the independent predictors of increased
circulating level of EPCs (Table 4), a number of enroll-
ment variables were utilized (Tables 2 and 3). Multiple
linear regression analysis demonstrated that chronic
hepatitis B and EV bleeding were significantly and inde-
pendently associated with increased circulating level ofEPCs. By contrast, hepatitis C, decompensated LC, and
serum AST level were inversely and independently pre-
dictive of decreased circulating level of EPCs.
To compare the angiogenesis ability and EPC function
between study patients and healthy control subjects,
MNC culture for EPC was performed (Figure 2). Inter-
estingly, the results showed that the cluster formation
(p< 0.001), tubular formation (p< 0.0001), and network
formation (p< 0.0001) were remarkably lower in LC
patients than in healthy control subjects. In addition, the
accumulative tubular length (P< 0.0001) was notably
reduced in LC patients than in healthy control subjects.
Furthermore, the number of transwell migratory EPCs
was substantially lower in LC patients as compared with
those in healthy control subjects (p< 0.0001).
Discussion
Several striking implications were noted in this study
that investigated the number and function of circulating
of EPCs, plasma levels of VEGF, SFD-1α, and MCA in
circulation. First, the circulating levels of SDF-1α as well
as the degree of both early and late MCA were remark-
ably higher in LC patients compared with those in
healthy control subjects. Second, the circulating number
of EPCs was notably lower in LC patients than that in
Figure 1 Flow Cytometric and ELISA Analysis among Patients With and Without HCC and in Normal Control Subjects. A) Circulating
number of endothelial progenitor cells (EPCs). For CD31/CD34+ cells, * vs. †, p< 0.04. For CXCR4+/CD34+ cells, * vs. †, p< 0.03. HCC
(−) =without hepatocellular carcinoma (n = 66); HCC (+) =with hepatocellular carcinoma (n = 12). B) Plasma level of vascular endothelial growth
factor (VEGF). * vs. †, p< 0.035. C) Plasma level of stromal cell-derived factor (SDF)-1α. * vs. †, p< 0.04. Symbols (*, †) indicate significant
difference (at 0.05 level) (by Wilcoxon rank sum test with Bonferroni’s correction).
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of EPCs was markedly decreased, whereas the degree of
late MCA in circulation was significantly increased in
Child’s class B and C patients compared with those in
Child’s class A.
Surprisingly, while the association between increased
serum levels of soluble angiogenic factors and chronic
liver disease and HCC has been extensively investigated,Table 4 Multiple Stepwise Linear Regression Analysis of Inde
Variables CD31/CD34
Coefficient β p value Coef
Age −0.009 0.059
Hepatitis B 0.340 0.011
Hepatitis C −
EV bleeding
Liver cirrhosis† 0.352 0.087
AST −
AST = aspartate aminotransferase; EPC = endothelial progenitor cells; EV = esophage
* Variables of Tables 2 and 3 were enrolled for analysis.
† indicated decompensated liver cirrhosis.circulating EPC level in LC patients has seldom been
reported [25]. One important finding in the current
study is that the number of circulating EPCs was notably
reduced in patients with LC compared to that in age-
and gender-matched healthy control subjects. Of par-
ticularly interest is that, when compared with Child’s
class A patients, this biomarker was further decreased in
those in Child’s class B and C. Our results, therefore,pendent Predictors of Increased Circulating Level of EPCs*
KDR/CD34 CXCR4/CD34







Figure 2 In vitro function assessment of endothelial progenitor cells with transwell and matrigel tube formation assay. A to C) The
transwell migratory activity of endothelial progenitor cells (EPCs) (100 x) was notably reduced (C) in liver cirrhosis (LC) group than in healthy
control group (* vs. normal control, p< 0.0001) (n = 6). D to F). Illustration of angiogenesis using passages 2 of culturing cells (all pictures were
observed under microscope of 400 x). The cluster formation (red arrows), tubular formation (black arrows) and network formation (blue dot lines)
were notably higher in normal control than in LC patients (G to J). (* vs. normal control, all p values< 0.001) (n = 6) High-power field (HPF).
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tion was independently correlated to the reduction in
circulating number of EPCs (Table 4). Interestingly, Yu
et al.. has recently demonstrated dynamic changes in the
levels of circulating EPCs in cirrhotic liver using a rat
model of HCC [34]. The results of their experiment
revealed a gradual increase in the number of circulating
EPCs up to 4 weeks after the onset of liver disease, fol-
lowed by a gradual drop to less than the baseline level at
more advanced stage of LC [34]. Accordingly, our find-
ings corroborate those from Yu et al.[34]. Of importance
was that our findings may, therefore, encourage the use
of circulating EPC number as an accessory tool in our
clinical practice for evaluating the severity of decompen-
sation in liver function.
Although elevations in the serum levels of soluble
angiogenic factors are well-documented in the setting of
advanced liver disease as in LC and HCC, the reason for
the reduction in circulating number of EPCs in LC
patients compared with that in healthy control subjects
remains unclear. The results of the present study pro-
vided several possible explanations for the phenomenon.
First, since the progression from fibrosis to cirrhosis, the
end-point of chronic liver diseases, is characterized by a
chronic and persistent inflammatory reaction [35.36], we
suggest that such chronic inflammation, in addition tostimulating the local release of angiogenic factors by
hepatic stellate cells and sinusoidal endothelial cells
[35,36], may at the same time suppress the mobilization
of EPCs from bone marrow into the circulation. Our hy-
pothesis is supported by the findings of previous studies
[16,17] showing a significant decrease in the circulating
number of EPCs in patients with hypertension, hyper-
cholesterolemia, current smoking, and diabetes mellitus
that are well-known risk factors for coronary artery dis-
ease and indexes of chronic inflammatory disease. Sec-
ond, substantial reduction in circulating EPCs has also
reported in patients with decompensated heart failure
[19] that is believe to be attributable to an exhaustion of
the sources of EPCs. We propose that decompensated
heart failure and decompensated LC are two sides of the
same coin. Consistently, 50 % of our patients have been
identified to have decompensated LC. This proposed
mechanism is supported by the findings from both ex-
perimental [34] and clinical observational [19] studies.
Surprisingly, contrary to the findings of the present
study, a recent investigation [25] demonstrated a higher
circulating level of EPCs (i.e. triple staining of the sur-
face EPC marker: CD34/KDR/AC133) in patients with
HCC than in those with LC. Moreover, that study also
showed a higher number of circulating EPCs in LC
patients than that in normal controls. Although the
Chen et al. Journal of Biomedical Science 2012, 19:66 Page 9 of 11
http://www.jbiomedsci.com/content/19/1/66discrepancy in results between ours and those from that
study [25] seems paradoxical, there may be three pos-
sible explanations. First, the treatment status of the
patients was different in the two studies. While the pre-
vious report enrolled patients waiting for HCC treat-
ment, the current study recruited patients with HCC
after treatment, including percutaneous ethanol injec-
tion, radiation therapy, radiofrequency ablation, liver
lobectomy, or chemotherapy. Second, the degree of de-
compensation in liver function and the staging for
advanced LC may not be identical between the two stud-
ies. Finally, differences in sample size, exclusion criteria,
methodology for identification of EPCs (CD34/KDR/
AC133 in the recent study [25] vs. CD31/CD34, KDR/
CD34 and CXCR4/CD34 in the present study) may also
contribute to the discrepancy in results between the two
studies. Another interesting finding is that, as compared
with LC patients without HCC, those with HCC had sig-
nificantly higher circulating number of E3. Besides, LC
patients with HCC also had notably higher plasma level
of VEGF compared to that in healthy control subjects.
In terms of subgroup analysis, therefore, our results
were comparable to those of the recent report [25].
The role of SDF-1α has been established as the ligand
of CXCR4+ cells. It has also been reported to play an
essential role in mobilizing EPCs from bone marrow to
circulation to reach ischemic tissue/organ for angiogen-
esis and organ repair/regeneration [15]. According to a
recent report from Hong et al. [35], activation of
CXCR4 receptor by SDF-1α is profibrogenic in the liver
through activation of hepatic stellate cells. In addition
to the elevated number of circulating cells with E3 in
LC patients with HCC than in LC patients without
HCC, another interesting finding in the present study is
the substantial increase in plasma level of SDF-1α in
LC patients with HCC compared to that in those LC
patients without HCC and healthy subjects. Therefore,
the results from this clinical observational investigation
further strengthen those from Hong’s in vivo and
in vitro studies [35].
The most important finding in the current study is
that, compared with that in the healthy subjects, the
capacity for angiogenesis (i.e. cluster, network and tubu-
lar formations) was markedly impaired in LC patients.
Besides, the transwell migratory ability of EPCs was sig-
nificantly reduced in LC patients compared to that of
the healthy controls. These novel findings implicate that
not only was the number of circulating EPCs notably
lower in LC patients, but the function of circulating
EPCs was also remarkably impaired in this patient
population.
Previous studies by other authors and those from our
group have identified an association between enhanced
systemic cytokine levels, inflammatory responses, andcellular apoptosis after myocardial infarction [33,36].
One of the principal findings in the present study is that
MCA in circulation was substantially elevated in LC
patients than that in healthy subjects. Additionally, late
MCA was further increased in Child’s class B and C
patients than those in class A. Taking into consideration
the fact that chronic liver disease is a process of persist-
ent inflammation, our findings (i.e. MCA) are believed
to be the results of chronic inflammatory process in
these patients. In this way, these distinctive findings are
consistent with those from previous studies [33,36].
In this study, EV bleeding was significantly and inde-
pendently correlated to an increased number of circulat-
ing EPCs. This finding suggests that EV bleeding with
acute blood loss may stimulate generation and release of
hematopoietic and non-hematopoiectic stem/progenitor
cells from bone marrow into the circulation. On the
other hand, increased serum level of AST might impli-
cate more severe inflammation and damage in liver par-
enchyma that might, in turn, suppress the mobilization
of EPCs from bone marrow to circulation.
This study has limitations. First, we have no idea
regarding the explanation for the finding of chronic
hepatitis B as a significant and independent factor asso-
ciated with an increased number of circulating EPCs in
this study. Similar difficulty in explanation is applicable
to the negative association between the presence of
hepatitis C and a decreased number of circulating EPCs.
Second, despite our interesting findings, the sample size
of our series is relatively small. All conclusions based on
our results, therefore, are tentative and need further sup-
port from well-controlled clinical studies of larger scale.
Conclusion
The results of our study demonstrated that the level,
angiogenic ability, and function of circulating EPCs were
significantly reduced in cirrhotic patients compared with
those in healthy subjects. By contrast, the plasma levels
of SDF-1α and circulating MCA were substantially
enhanced in LC patients. These findings may highlight
the fact that circulating level of EPCs is reduced not only
in patients with risk factors of coronary artery disease
but also in patients with LC, especially in those patients
with decompensated LC.
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